BV, Ombitasvir; DSV, Dasabuvir); GZR, Grazoprevir; GLE, Glecaprevir; EBR, Elbasvir; PIB
BV, Ombitasvir; DSV, Dasabuvir); GZR, Grazoprevir; GLE, Glecaprevir; EBR, Elbasvir; PIB, Pibrentasvir; VEL, Velpatasvir; RBV, Ribavirin; ASV, Asunaprevir. HBV, hepatitis B virus; HIV, human immunodeficiency virus; CKD, chronic kidney disease; PWID, Persons who inject drugs; LC, liver cirrhosis; HCC, hepatocellular carcinoma. TACR, The Taiwan HCV Registry. n/a, not offered. This Study Total Study population, n Gender (male), n Age (years), mean SD HBV, n HIV, n CKD, n PWID, n LC, n Active HCC, n Pre-treatment FIB-4, imply SD With prior treatment, n HCV genotype, n 1 1a 1b two 2a 2b 3a, 3b, 3k six, 6a, 6n, 6n, 6w DAA regimes, n DCV/ASV SOF/RBV SOF/LDV PrOD EBR/GZR SOF/VEL GLE/PIB SOF/DCV DAA termination, n 18 (12 ) 24 (16 ) 34 (23 ) 13 (9 ) 18 (12 ) 4 (three ) 31 (21 ) 5 (3 ) 2 (1 ) 18 (17 ) 24 (22 ) 34 (32 ) 13 (12 ) 18 (17 ) 0 (0 ) 0 (0 ) 0 (0 ) 2 (two ) 0 (0 ) 0 (0 ) 0 (0 ) 0 (0 ) 0 (0 ) 4 (ten ) 31 (78 ) five (13 ) 0 (0 ) 24 (10 ) 61 (26 ) 64 (27 ) 34 (14 ) 29 (12 ) five (2 ) 20 (8 ) five (two ) 21 (9 ) three (2 ) 10 (7 ) 43 (30 ) five (three ) 36 (25 ) 17 (12 ) 8 (six ) 21 (15 ) three (three ) 7 (7 ) 42 (40 ) four (4 ) 20 (19 ) 14 (13 ) 1 (1 ) 13 (13 ) 0 (0 ) 3 (eight ) 1 (3 ) 1 (three ) 16 (41 ) 3 (8 ) 7 (18 ) 8 (21 ) five (2 ) 7 (3 ) 107 (45 ) 112 (47 ) 147 77 (54 ) 60 13 7 (5 ) 8 (six ) 8 (six ) 9 (7 ) 45 (35 ) 20 (16 ) 3.86 3.19 31 (22 ) Genotype-Specific 107 53 (50 ) 61 12 four (4 ) 5 (five ) 6 (6 ) five (five ) 39 (40 ) 16 (16 ) 4.09 three.28 27 (27 ) Pan-Genotype 40 24 (67 ) 57 14 3 (9 ) 3 (ten ) two (six ) four (13 ) six (19 ) 4 (13 ) three.14 2.71 four (11 ) TACR (Chen et al.) Failure Instances 236 115 (49 ) 63 16 (7 ) four (2 ) 40 (17 ) three (1 ) 104 (44 ) 23 (10 ) n/a 64 (27 )The all round clinical characteristics of our study subjects have been related to these of the larger TACR cohort but with particular distinctions. As an illustration, the percentages of coinfection of HIV and persons who inject drugs (PWID) have been considerably greater in our cohort, though the percentages of chronic kidney AZD4625 GPCR/G Protein illness (CKD), liver cirrhosis, and early UCB-5307 Autophagy termination had been substantially higher in the TACR cohort. The percentage of glecaprevir/pibrentasvirViruses 2021, 13,Viruses 2021, 13, x FOR PEER REVIEW6 of6 ofwas significantly greater in our cohort even though the percentage of sofosbuvir/ribavirin was greater in TACR cohort. With regard to virus characteristics, the percentage of genotype six was higher in TACR cohort. With regard to virus functions, the percentage of genotype six was drastically greater in our cohort than within the TACR cohort. substantially greater in our cohort than within the TACR cohort. Moreover, these 147 sufferers could be categorized into two groups: one group (107 Furthermore, these 147 sufferers could be categorized into two groups: one particular group individuals) received genotypespecific DAAs although the other a single (40 sufferers) received pan (107 individuals) received genotype-specific DAAs even though the other 1 (40 individuals) regenotype DAAs. Sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and sofos ceived pangenotype DAAs. Sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and sofosbubuvir/daclatasvir are pangenotypic whereas the earlier DAAs which include sofosbuvir, sofos vir/daclatasvir are pangenotypic whereas the earlier DAAs such as sofosbuvir, sofosbubuvir/ledipasvir, daclatasvir/asunaprevir, dasabuvir plus ombitasvir/paritaprevir/ri vir/ledipasvir, daclatasvir/asunaprevir, dasabuvir plus ombitasvir/paritaprevir/ritonavir, tonavir, and elbasvir/grazoprevir are genotypespecific. The clinical characteristics of and elbasvir/grazoprevir are.